Characterization of Mice Expressing Ins1 Gene Promoter Driven CreERT Recombinase for Conditional Gene Deletion in Pancreatic β-cells
Overview
Gastroenterology
Affiliations
Gene manipulation using Cre-loxP recombination has proven to be an important approach for studying the impact of gene expression on pancreatic β-cell biology. We report the generation of a transgenic mouse line that enables a highly specific system for conditional gene manipulation within β-cells and achieve tissue specific and temporally regulated deletion of the Ctnnb1 (β-catenin) gene in pancreatic β-cells. cDNA encoding Cre recombinase fused to modified estrogen receptor (CreERT) under control of mouse insulin 1 gene promoter (Ins1) was used to construct the mouse line Tg(Ins1-Cre/ERT)1Lphi, also termed MIP1-CreERT. In a cross of MIP1-CreERT with a ROSA26/LacZ reporter strain, tamoxifen [Tmx] - dependent β-galactosidase expression occurred within pancreatic β-cells but not in other organ systems. Intraperitoneal glucose tolerance tests and glucose-stimulated changes in β-cell cytoplasmic calcium concentration were not adversely affected in adult MIP1-CreERT. A mouse line with floxed Ctnnb1 gene (Ctnnb1f/f) was crossed with the MIP1-CreERT line to generate a mouse model for inducible β-cell specific deletion of β-catenin gene (Ctnnb1f/f:MIP1-CreERT). Ctnnb1f/f:MIP1-CreERT mice and Ctnnb1f/f littermate controls, were injected with Tmx as adults to knock down β-catenin production in the majority of pancreatic β-cells. These mice showed normal glucose tolerance, islet cyto-architecture and insulin secretion. A novel protein fraction of 50Kd, immunoreactive with anti-β-catenin was observed in islet extracts from Ctnnb1f/f:MIP1-CreERT[Tmx] mice but not MIP1-CreERT-negative Ctnnb1f/f[Tmx] controls, indicating possible presence of a cryptic protein product of recombined Ctnnb1 gene. The MIP1-CreERT mouse line is a powerful tool for conditional manipulation of gene expression in β-cells.
Anderson C, Kulkarni A, Maier B, Huang F, Figatner K, Chakraborty A J Biol Chem. 2025; 301(2):108209.
PMID: 39832654 PMC: 11869520. DOI: 10.1016/j.jbc.2025.108209.
Izadifar M, Massumi M, Prentice K, Oussenko T, Li B, Elbaz J Stem Cell Res Ther. 2024; 15(1):486.
PMID: 39696686 PMC: 11656860. DOI: 10.1186/s13287-024-04059-7.
Metabolic control of adaptive β-cell proliferation by the protein deacetylase SIRT2.
Wortham M, Ramms B, Zeng C, Benthuysen J, Sai S, Pollow D bioRxiv. 2024; .
PMID: 38464227 PMC: 10925077. DOI: 10.1101/2024.02.24.581864.
Sox9 regulates alternative splicing and pancreatic beta cell function.
Puri S, Maachi H, Nair G, Russ H, Chen R, Pulimeno P Nat Commun. 2024; 15(1):588.
PMID: 38238288 PMC: 10796970. DOI: 10.1038/s41467-023-44384-8.
Disrupted RNA editing in beta cells mimics early-stage type 1 diabetes.
Knebel U, Peleg S, Dai C, Cohen-Fultheim R, Jonsson S, Poznyak K Cell Metab. 2023; 36(1):48-61.e6.
PMID: 38128529 PMC: 10843671. DOI: 10.1016/j.cmet.2023.11.011.